Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Safety of Urate Elevation in Parkinson's Disease (SURE-PD)

This study has been completed.
Sponsor:
Collaborators:
Massachusetts General Hospital
Harvard School of Public Health
University of Rochester
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
Michael Schwarzschild, The Parkinson Study Group
ClinicalTrials.gov Identifier:
NCT00833690
First received: January 27, 2009
Last updated: May 30, 2014
Last verified: May 2014
History of Changes
Results First Received: December 26, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Parkinson Disease
Interventions: Drug: Placebo
Drug: inosine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
[A:]Placebo Placebo to produce no urate elevation
[B:]Mild Inosine to produce a mild urate elevation
[C.]Moderate Inosine to produce a moderate urate elevation

Participant Flow:   Overall Study
    [A:]Placebo     [B:]Mild     [C.]Moderate  
STARTED     25     24     26  
COMPLETED     21     22     26  
NOT COMPLETED     4     2     0  
Withdrawal by Subject                 1                 0                 0  
Discontinued study drug                 3                 2                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
[A:]Placebo Placebo to produce no urate elevation
[B:]Mild Inosine to produce a mild urate elevation
[C.]Moderate Inosine to produce a moderate urate elevation
Total Total of all reporting groups

Baseline Measures
    [A:]Placebo     [B:]Mild     [C.]Moderate     Total  
Number of Participants  
[units: participants]
 		  25     24     26     75  
Age  
[units: years]
Mean ± Standard Deviation 		  61  ± 11     62  ± 10     62  ± 11     62  ± 10  
Gender  
[units: participants]
 		       
Female     13     14     14     41  
Male     12     10     12     34  
Ethnicity (NIH/OMB)  
[units: Participants]
 		       
Hispanic or Latino     0     2     0     2  
Not Hispanic or Latino     25     22     26     73  
Unknown or Not Reported     0     0     0     0  
Race (NIH/OMB)  
[units: Participants]
 		       
American Indian or Alaska Native     0     0     0     0  
Asian     0     0     0     0  
Native Hawaiian or Other Pacific Islander     0     0     1     1  
Black or African American     0     0     0     0  
White     24     22     24     70  
More than one race     0     0     0     0  
Unknown or Not Reported     1     2     1     4  
Region of Enrollment  
[units: participants]
 		       
United States     25     24     26     75  
Years since symptom onset  
[units: Years]
Mean ± Standard Deviation 		  2.4  ± 1.3     2.8  ± 1.9     2.2  ± 2.0     2.4  ± 1.8  
Years since diagnosis  
[units: Years]
Mean ± Standard Deviation 		  1.1  ± 1.3     1.3  ± 1.0     0.6  ± 0.7     1.0  ± 1.1  
Serum Urate  
[units: mg/dL]
Mean ± Standard Deviation 		  4.5  ± 0.7     4.3  ± 1.2     4.6  ± 0.9     4.5  ± 0.9  
Serum urate in women  
[units: mg/dL]
Mean ± Standard Deviation 		  4.4  ± 0.8     3.9  ± 1.3     4.4  ± 0.8     4.2  ± 1.0  
Serum urate in men  
[units: mg/dL]
Mean ± Standard Deviation 		  4.7  ± 0.5     5.0  ± 0.8     4.9  ± 0.9     4.8  ± 0.7  
United Parkinson's Disease Rating Scale (UPDRS) score total [1]
[units: points]
Mean ± Standard Deviation 		  23  ± 10     20  ± 9     21  ± 10     22  ± 10  
Montreal Cognitive Assessment (MoCA) [2]
[units: Score]
Mean ± Standard Deviation 		  28  ± 1.9     28  ± 1.8     28  ± 2.0     28  ± 1.9  
Geriatric Depression Scale-short form (GDS-S) [3]
[units: Score]
Mean ± Standard Deviation 		  1.5  ± 1.9     1.4  ± 1.7     1.8  ± 2.6     1.5  ± 2.1  
[1] The UPDRS is designed to monitor disability and impairment due to Parkinson's disease. It comprises several parts. Part I evaluates "Mentation, Behavior, and Mood" (with a maximum of 16 points; more points are worse); Part II evaluates "Activities of Daily Living" (with a maximum of 52 points); Part III entails a "Motor Examination" (with a maximum of 108 points). Total score of Parts I-III sums the points from all parts and thus can range from a minimum of 0 (best) to a maximum of 176 (worst).
[2] The MoCA assesses short term and working memory, visual-spatial abilities, executive function, attention, concentration, language and orientation. The total score ranges from 0 to 30 (highest function).
[3] GDS-S is a short 15 'yes/no' question instrument for assessing depression in older adults. Questions are answered by the research participant (i.e., self-rater). Scores range range from 0 to 15 and higher scores represent greater depression. Scores of 5-9 and >9 have been correlated with mild and moderate-severe depression, respectively.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Tolerability   [ Time Frame: 6 months ]
  Show Outcome Measure 1

2.  Primary:   Tolerability   [ Time Frame: 24 months ]
  Show Outcome Measure 2

3.  Primary:   Safety   [ Time Frame: 24 months ]
  Show Outcome Measure 3

4.  Secondary:   CSF Urate (All Patients)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 4

5.  Secondary:   CSF Urate (Females)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 5

6.  Secondary:   CSF Urate (Males)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 6

7.  Secondary:   CSF Urate as a Proportion of Baseline Serum Urate (All Patients)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 7

8.  Secondary:   CSF Urate as a Proportion of Baseline Serum Urate (Females)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 8

9.  Secondary:   CSF Urate as a Proportion of Baseline Serum Urate (Males)   [ Time Frame: 12 weeks ]
  Show Outcome Measure 9

10.  Secondary:   Serum Urate   [ Time Frame: Screening Visits, up to 45 days prior to Baseline Visit. Specifically, Screening Visit 1 occurred between day -45 and -4; Screening Visit 2 occurred between day -43 and -2. ]
  Show Outcome Measure 10

11.  Secondary:   Serum Urate   [ Time Frame: Baseline Visit ]
  Show Outcome Measure 11

12.  Secondary:   Serum Urate   [ Time Frame: Visit 01 (Week 2; 14 +/- 3 days after Baseline Visit) ]
  Show Outcome Measure 12

13.  Secondary:   Serum Urate   [ Time Frame: Visit 02 (Week 4; 28 +/- 3 days after Baseline Visit) ]
  Show Outcome Measure 13

14.  Secondary:   Serum Urate   [ Time Frame: Visit 03 (Week 6; 42 +/- 3 days after Baseline Visit) ]
  Show Outcome Measure 14

15.  Secondary:   Serum Urate   [ Time Frame: Visit 04 (Week 9; 63 +/- 5 days after Baseline Visit) ]
  Show Outcome Measure 15

16.  Secondary:   Serum Urate   [ Time Frame: Visit 05 (Week 12; 84 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 16

17.  Secondary:   Serum Urate   [ Time Frame: Visit 06 (Month 6; 180 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 17

18.  Secondary:   Serum Urate   [ Time Frame: Visit 07 (Month 9; 270 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 18

19.  Secondary:   Serum Urate   [ Time Frame: Visit 08 (Month 12; 360 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 19

20.  Secondary:   Serum Urate   [ Time Frame: Visit 09 (Month 15; 450 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 20

21.  Secondary:   Serum Urate   [ Time Frame: Visit 10 (Month 18; 540 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 21

22.  Secondary:   Serum Urate   [ Time Frame: Visit 11 (Month 21; 630 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 22

23.  Secondary:   Serum Urate   [ Time Frame: Visit 12 (Month 24; 720 +/- 7 days after Baseline Visit) ]
  Show Outcome Measure 23

24.  Secondary:   Serum Urate   [ Time Frame: End of Study Drug Visit (ESD) (Month 9-24; 263-727 days after Baseline Visit) ]
  Show Outcome Measure 24

25.  Secondary:   Serum Urate   [ Time Frame: Safety Visit (SV); 30 +/- 3 days following ESD or Month 24 Visit ]
  Show Outcome Measure 25

26.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 01 from Baseline (i.e., between -45 days and +2 weeks) ]
  Show Outcome Measure 26

27.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 02 from Baseline (i.e., between -45 days and +4 weeks) ]
  Show Outcome Measure 27

28.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 03 from Baseline (i.e., between -45 days and +6 weeks) ]
  Show Outcome Measure 28

29.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 04 from Baseline (i.e., between -45 days and +9 weeks) ]
  Show Outcome Measure 29

30.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 05 from Baseline (i.e., between -45 days and +12 weeks) ]
  Show Outcome Measure 30

31.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 06 from Baseline (i.e., between -45 days and +6 months) ]
  Show Outcome Measure 31

32.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 07 from Baseline (i.e., between -45 days and +9 months) ]
  Show Outcome Measure 32

33.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 08 from Baseline (i.e., between -45 days and +12 months) ]
  Show Outcome Measure 33

34.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 09 from Baseline (i.e., between -45 days and +15 months) ]
  Show Outcome Measure 34

35.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 10 from Baseline (i.e., between -45 days and +18 months) ]
  Show Outcome Measure 35

36.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 11 from Baseline (i.e., between -45 days and +21 months) ]
  Hide Outcome Measure 36

Measure Type Secondary
Measure Title Change in Serum Urate
Measure Description Change from an Average of Baseline and Screening Visits
Time Frame Visit 11 from Baseline (i.e., between -45 days and +21 months)  
Safety Issue No  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
[A:]Placebo Placebo to produce no urate elevation
[B:]Mild Inosine to produce a mild urate elevation
[C.]Moderate Inosine to produce a moderate urate elevation

Measured Values
    [A:]Placebo     [B:]Mild     [C.]Moderate  
Number of Participants Analyzed  
[units: participants]
 		  7     11     14  
Change in Serum Urate  
[units: mg/dL]
Mean ± Standard Deviation 		  -0.07  ± 0.59     2.53  ± 1.12     3.11  ± 1.46  

No statistical analysis provided for Change in Serum Urate



37.  Secondary:   Change in Serum Urate   [ Time Frame: Visit 12 from Baseline (i.e., between -45 days and +24 months) ]
  Show Outcome Measure 37

38.  Secondary:   Change in Serum Urate   [ Time Frame: Safety Visit (SV) from Baseline (i.e., between -45 days and +760 days [+1 month after ESD Visit]) ]
  Show Outcome Measure 38

39.  Secondary:   Change in Serum Urate   [ Time Frame: Safety Visit (SV) from End of Study Drug Visit (ESD); i.e., between +263 and +760 days) ]
  Show Outcome Measure 39


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Michael A. Schwarzschild, MD, PhD
Organization: The Parkinson Study Group
phone: 617-724-9611
e-mail: mschwarzschild@partners.org


No publications provided by The Parkinson Study Group

Publications automatically indexed to this study:
Parkinson Study Group SURE-PD Investigators, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.


Responsible Party: Michael Schwarzschild, The Parkinson Study Group
ClinicalTrials.gov Identifier: NCT00833690     History of Changes
Other Study ID Numbers: INO-PD-P2-2008
Study First Received: January 27, 2009
Results First Received: December 26, 2013
Last Updated: May 30, 2014
Health Authority: United States: Food and Drug Administration